Navigation Links
Early detection of cancer: The FDA approves procedure discovered by EPFL researchers
Date:6/14/2010

Researchers at the Ecole Polytechnique Fdrale de Lausanne (EPFL) in Switzerland have established a procedure where cancerous tumors in the bladder become fluorescent and are more easily discoverable under blue light. The Food and Drug Administration (FDA) approved the technique already in practice in Europe for the American market. Under the name Cysview, the product is commercialized by Photocure and GE Healthcare as the most efficient detection technique for early stage bladder cancer.

Bladder cancer is the fourth most common cancer in men and the eighth most common in women in the US. Being extremely difficult to detect in its early stages, even by the trained eye of a urologist, the importance of increasing its detectability is paramount for the complete removal of the tumors which helps to delay tumor recurrence.

Helping diagnostics and surgical removal

Cysview is instilled in the bladder. After penetrating the bladder wall it is metabolized mainly by the malignant cells, causing them to produce a fluorescent compound. The doctor then examines the bladder with an endoscope camera equipped with a blue light system: the tumors appear as easily-recognizable red spots. The procedure is not only helpful in diagnosing cancer, it is also useful for the surgeon when removing these small tumors, as he can be assured that the tumor is completely removed when no fluorescence remains.

"With Cysview, even a child can recognize these tumors", says Hubert van den Bergh, head of the project at EPFL. Then, he shows several examples where tumors have been forced out of hiding.

American experts have noticed a significant improvement with Cysview, compared to standard white light cystoscopy. A fact that is also supported in Europe with Hexvix, the European name for the product: experts have shown that the rate of recurrence of bladder cancer is significantly lower after treatment.

Application to other types of cancers

"In the future, similar procedures could be used, for instance for colon cancer or other tumors found in the hollow organs", explains Hubert van den Bergh. EPFL's Norwegian partner Photocure, owner of Hexvix/Cysview, is currently involved in developing this domain.

For the moment, this procedure is the only one of its kind approved by the FDA for use in the bladder. "There is no procedure as efficient," insists Georges Wagnires, responsible for the technology transfer in this project at EPFL, "and the market is therefore potentially very large." The approval by the FDA comes after a more than a decade of development work by the scientists at EPFL and their academic partners from the University Hospital Center (CHUV), the University of Lausanne and Photocure.


'/>"/>

Contact: Georges Wagnires
georges.wagnieres@epfl.ch
41-787-423-511
Ecole Polytechnique Fdrale de Lausanne
Source:Eurekalert  

Related medicine news :

1. Nuvo Research announces early redemption of 5% convertible debentures
2. A better sign of blood vessel narrowing and early coronary artery disease
3. Bad Behavior as a Kid Linked to Early Death in Men
4. Promising new neuroimaging techniques for early detection of Alzheimers disease
5. Symptoms have little value for early detection of ovarian cancer
6. Immune memory formation seen in early stages of viral infection
7. Symptoms Alone Dont Spot Ovarian Cancer Early
8. Early Factors Predict Later-Life Stroke Risk, from the Harvard Health Letter
9. Early menopause can result in earlier onset dementia
10. New Test Might Smell Early Stage Lung Cancer
11. Early EKG Seems to Improve Odds After Heart Attack
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Early detection of cancer: The FDA approves procedure discovered by EPFL researchers
(Date:6/28/2017)... , ... June 28, 2017 , ... ... management and financial planning assistance to clients in southern Montana, is announcing a ... by Zoo Montana. , The outreach programs offered by Zoo Montana provide students ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... consulting firm servicing communities throughout the greater Cincinnati metropolitan area, is teaming up ... temporary lodgings for families with children receiving treatment in nearby hospitals. , Ronald ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... DrugDev ... study is whether they can trust the sponsor to pay them correctly and on ... sponsors and CROs establish payment strategies that encourage sites to work on their studies. ...
(Date:6/27/2017)... ... 2017 , ... The Congressional Budget Office (CBO) projects that the Better Care ... Protection and Affordable Care Act (ACA), would result in 22 million Americans losing their ... , More than 20 million Americans have gained health insurance under the ACA, and ...
(Date:6/27/2017)... ... , ... A January 18th article on medGadget reports that the ... the year 2024 according to a new report. The article also notes that the ... Los Angeles area clinic Beverly Hills Periodontics & Dental Implant Center says that it ...
Breaking Medicine News(10 mins):
(Date:6/19/2017)... HORSHAM, Pa. , June 19, 2017  Researchers ... announced today that they will host a live, complimentary ... Perspectives from the benchtop to the real world" on ... PM EDT. This webinar will feature ... a rare look into the manipulation techniques abusers use ...
(Date:6/14/2017)... The Bio Supply Management Alliance (BSMA) has ... and the Biomedical Manufacturing Network to advance ... California by providing a platform for ... workforce development. The primary focus of this alliance is ... well as small and mid-sized biomedical companies. ...
(Date:6/11/2017)... June 10, 2017  Eli Lilly and Company (NYSE: ... Phase 3 studies of galcanezumab, an investigational treatment for ... data on several key secondary endpoints for galcanezumab compared ... these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented ... meeting in Boston . ...
Breaking Medicine Technology: